Conferences - Results from #280

Viewing 281-300 of 11869 articles

ESMO 2024: SAABR: Single Arm Phase II Study of Androgen Receptor Pathway Inhibitor + Atezolizumab + GnRH analog and Stereotactic Body Radiotherapy to the Prostate in Men with De Novo Hormone-sensitive Metastatic Prostate Cancer

ESMO 2024: Association of PD-L1 Expression with Clinical Response to TAR-200 in the Phase 2b SunRISe-1 Trial

ESMO 2024: Intensification of Systemic Treatment for Poor Risk Disease

ESMO 2024: The STAMPEDE2 (177Lu-PSMA-617) Trial: A Phase III, Randomised, Open-Label Trial in Patients with Metastatic Prostate Cancer Starting ADT

ESMO 2024: The STAMPEDE2 Stereotactic Ablative Body Radiotherapy Trial: A Phase III, Randomized, Open-Label Trial in Patients with Newly Diagnosed Oligometastatic Prostate Cancer Starting ADT

ESMO 2024: The STAMPEDE2 Niraparib-Abiraterone Acetate + Prednisolone Trial: A Phase III, Randomized, Open-Label Trial in Patients with Metastatic Prostate Cancer with a Deleterious Alteration in a HRR Gene Starting ADT

ESMO 2024: LEGEND: A Phase 1/2 Study of EG-70 (Detalimogene Voraplasmid) Intravesical Monotherapy for Patients with BCG-Unresponsive NMIBC with CIS

ESMO 2024: Phase 1/2 Trial of Oral Masofaniten (EPI-7386) in Combination with Enzalutamide Compared to Enzalutamide Alone in Metastatic Castration-Resistant Prostate Cancer

ESMO 2024: Enzalutamide with or Without Leuprolide in Patients with High-Risk Biochemically Recurrent Prostate Cancer: EMBARK Post Hoc Analysis by Age

ESMO 2024: PSMA-PET and PROMISE Re-Define Stage and Risk in Patients with Prostate Cancer

ESMO 2024: Enfortumab Vedotin + Pembrolizumab Outcomes Outside Clinical Trials and Biomarkers of Benefit in Patients with Advanced Urothelial Carcinoma: Analysis of the UNITE Study

ESMO 2024: Radium-223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Patients with Bone Metastatic Castration-Resistant Prostate Cancer: First Results of EORTC-GUCG 1333/PEACE-3

ESMO 2024: RUTIVAC-1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase I Trial to Evaluate the Immunomodulatory Effect of RUTI® in Individuals with High-Risk Non-Muscle-Invasive Bladder Cancer Treated with Intravesical BCG

ESMO 2024: Invited Discussant – EORTC-GUCG 1333/PEACE-3

ESMO 2024: First Results from ZZFIRST: a Randomized Phase II Trial of Enzalutamide with or without Talazoparib in Metastatic Hormone-naïve Prostate Cancer

ESMO 2024: Xaluritamig, a STEAP1 x CD3 XmAb 2+1 Immune Therapy, in Patients With Metastatic Castration-Resistant Prostate Cancer: Initial Results From Dose Expansion Cohorts in a Phase 1 Study

ESMO 2024: Symptomatic Skeletal Events, Health-Related Quality of Life and Pain in a Phase 3 Study of [177Lu]Lu-PSMA-617 in Taxane-Naive Patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer: Third Interim Analysis of PSMAfore

ESMO 2024: PSMA PET as a Game Changer for Decision Making?

ESMO 2024: Study EV-103 Dose Escalation/Cohort A: 5y Follow-Up Of First-Line Enfortumab Vedotin + Pembrolizumab in Cisplatin-Ineligible Locally Advanced Or Metastatic Urothelial Carcinoma

ESMO 2024: Subcutaneous Nivolumab vs Intravenous Nivolumab in Patients with Previously Treated Advanced or Metastatic Clear Cell Renal Cell Carcinoma: Updated Efficacy and Safety Results from CheckMate 67T

10
11
12
13
14
15
16
17
18
19